Homozygous Familial Hypercholesterolemia (HoFH)

The visual science of a first-in-class treatment in HoFH.

This excerpt is taken from our 3D animation work for a biopharmaceutical company that developed an FDA-approved orphan drug, aimed at treating the rare genetic disease homozygous familial hypercholesterolemia (HoFH).

This video explores the activity within the body of a person affected with HoFH — explaining the normal and abnormal functions of LDL-C.


3D animations, multiple language videos, 3D illustrations - online, banner & brochure


Juxtapid (USA) & Lojuxta (EU)


Aegerion Pharmaceuticals

HoFH 3D animation
View HoFH Case Study

What is
Homozygous Familial Hypercholesterolemia (HoFH)

Familial hypercholesterolemia (FH), an autosomal codominant disease, is characterized by high levels of LDL cholesterol and a high incidence of coronary artery disease (CAD).

Homozygous Familial Hypercholesterolemia, or HoFH, is a rare genetic lipid disorder usually caused by defects in the low-density lipoprotein, or LDL, receptor genes, inherited from both parents, resulting in impaired or total loss of function in the LDL receptor.

references: www.circ.ahajournals.org Article: Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation / J. Ferrieres, MD, MSc; J. Lambert, PhD; S. Lussier-Cacan, PhD; J. Davignon, MD, Msc, aegerion.com

View HoFH Animation

It has been great working with you and we really appreciate all your work to make the videos become a reality.

Senior Director Business Development & US Marketing, Rare Disease, Aegerion Pharmaceuticals, Massachusetts, USA

Related Work

Need help with a project?

Get in touch and start your creative journey.

Contact Us

Next case study

New Business


+44 (0) 20 7183 9412 - UK

+1 646 568 4358 - USA


35A Victoria Rd.,
Surbiton, Surrey,